ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review.JAMA network open · 2026Pooled it
- Financial reimbursement for clinical trial participation costs: a pilot feasibility study.JNCI cancer spectrum · 2026Trial
- Physician- and Practice-Level Variation in Clinical Trial Participation Among Patients With Advanced Cancer.JAMA network open · 2026Article
- Independent cancer research in low- and middle-income countries: why it matters and how to build it.The oncologist · 2026Review
- Trials for Rare Cancers Are More Successful than those for Common Cancers.ESMO rare cancers · 2026Article
- Federal and Industry Sponsorship in US Cancer Clinical Trials.JAMA oncology · 2026Article
- Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).NPJ breast cancer · 2026Article
- FDA approvals for pediatric cancer indications using children's oncology group associated trials data.Journal of the National Cancer Institute · 2026Article
- Barriers and opportunities for participation in health policy decision-making by civil society groups organized for cancer in Chile: a qualitative study.Health research policy and systems · 2026Article
- Targeting urological cancers with CAR-T cell therapy: current landscape and future directions.Journal of translational medicine · 2026Review
- Frailty and neuropathy in chemotherapy patients: moderated mediation roles of fatigue and mindfulness on CIPN, anxiety, and depression.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Ensuring the Future of Cooperative Group Cancer Clinical Trials: A Call for Comprehensive Support and Prioritization.JCO oncology practice · 2026Article
- Oncology with common sense: beyond biologistic and pharmacological models.Ecancermedicalscience · 2026Article
- The role of regional and practice trial sites in nonrepresentative randomized cancer trial enrollment.Journal of the National Cancer Institute · 2025Article
- Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Advancing equitable access to innovation in breast cancer.NPJ breast cancer · 2025Article
- Clinical Proteomics, Quo Vadis?Proteomics · 2025Article
- Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- When to adjust for multiplicity in cancer clinical trials.Journal of the National Cancer Institute. Monographs · 2025Article
- BREAST CANCER: STEPS AND STUMBLES ON THE WAY TO PRECISION MEDICINE.Transactions of the American Clinical and Climatological Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThe conduct of cancer clinical research in the United States is supported by both private and public sponsors. Industry aims to obtain new drug approvals. Federally-sponsored trials examine a broad set of research questions that are not typically addressed by industry; these trials, which are also more commonly conducted in diverse populations, were recently shown to have contributed to gains of 14 million life-years for patients with cancer. Despite the different mandates, the proportion of patients who might participate in industry-sponsored versus federally-sponsored cancer studies is unknown.
methodsWe evaluated trial enrollment patterns from 2008 to 2022 using ClinicalTrials.gov data. The ratio of enrollments attributable to industry versus federal sponsors was estimated. A large set of estimates on the basis of different combinations of study characteristics were generated. Point estimates were determined as the mean of combinations and confidence limits by the IQR. Five-year intervals were examined to smooth annual variation.
resultsIn total, N = 26,080 studies were examined. The estimated enrollment ratio from 2018 to 2022 for all industry-sponsored versus federally-sponsored trials was 8.1 (IQR, 6.2-9.9). For adult trials, the ratio increased from 4.8 (IQR, 4.4-5.3) during 2008-2012 to 9.6 (IQR, 7.4-11.8) during 2018-2022; for trials in children, the ratio increased from 0.7 (IQR, 0.6-0.7) to 2.3 (IQR, 1.8-2.7). Despite increasing cancer incidence, enrollment counts for federally-sponsored trials were flat over the study period.
conclusionIn the United States, there is a growing reliance on industry to conduct cancer clinical research. Underinvestment in federally-sponsored research comes at a cost for both patients and researchers, with lost opportunities for scientific, clinical, and population advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.